Clinical Trial Update: A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma. [Phase 2]

View source ↗

Summary

A Phase 2 biomarker study evaluating the predictive value of biomarkers for the efficacy of neoadjuvant sintilimab plus SOX in gastric adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• SOX (SOX)
• Sintilimab (sintilimab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN